Special Concept Development UK Limited has informed the MHRA that the Patient Information Leaflet (PIL) for the batches listed in this notification do not contain the correct safety information.
Similar Posts
Form: Medicines: variation forms for a manufacturer’s licence
Forms to make a variation to a manufacturer’s licence.
Research: Review of risk minimisation for disabling and potentially long-lasting/irreversible side effects associated with fluoroquinolone antibiotics
Public Assessment Report on the review of risk minimisation for fluoroquinolone antibiotics.
Class 4 Medicines Defect Notification: Flamingo Pharma UK Ltd, Amitriptyline Hydrochloride 10mg, 25mg, 50mg Tablets, EL(25)A/52
Flamingo Pharma UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the products listed in this notification do not contain all the required safety information.
Professor Alastair Denniston: The future regulation of AI in healthcare
Creating a framework that is safe, fast and trusted.
Form: Blood bank compliance report template
Template for a blood bank compliance report and guidance on completing it.
Field Safety Notices: 7 to 11 July 2025
List of Field Safety Notices from 7 to 11 July 2025.